Edmonton – September 18, 2026 -- Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) reaffirmed its fiscal 2027 second-quarter guidance for sequential growth in net revenue and adjusted EBITDA, citing new EU-GMP capacity and expanding market share in Germany, Poland and the United Kingdom.
Safari Flower Company adds EU-GMP capacity after July certification
The Canadian medical cannabis producer said its recently acquired Safari Flower Company, which received EU-GMP certification in July, is expected to generate incremental net revenue and adjusted EBITDA in the coming quarters. The certification adds to Aurora's position as one of the world's largest indoor EU-GMP certified producers.
Poland delivers No. 1 market share by revenue as Germany performance holds steady
Aurora reported continued strong performance in Germany and Poland, the two largest medical cannabis markets in the European Union. The company holds the top market position by revenue in Poland, contributing to what it described as profitable international growth across the region.
UK acquisitions of Internode Pharma and HAP Pharma target further share gains
Aurora is expanding into the UK market following its acquisition of Internode Pharma and HAP Pharma Limited, moves the company expects will support additional market share growth in that country.
Balance sheet holds $149 million in cash with no debt as of June 30, 2026
The company reported $149 million in cash and no outstanding debt as of June 30, 2026. Aurora said its at-the-market equity program will be used only if its board determines doing so serves the company's best interest, and it plans continued investment in its international business over the next several quarters.
Executive Chairman and CEO Miguel Martin said the company is building value in global medical cannabis markets it estimates at $9 billion, pointing to Aurora's market share leadership across Canada, Europe, Australia and New Zealand as evidence of demand for its products among physicians and patients.